Pacific Biosciences Of California (PACB) Cash from Investing Activities (2010 - 2026)

Pacific Biosciences Of California's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $35.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 20.73% year-over-year to $35.9 million in Q1 2026; TTM through Mar 2026 was $106.1 million, a 47.84% decrease from a year earlier, with the FY2025 full-year figure at $115.4 million, down 6.9% from the prior year.
• Cash from Investing Activities grew to $35.9 million in Q1 2026 per PACB's latest filing, from $26.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $242.3 million in Q3 2023 and bottomed at -$98.6 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $26.0 million (2025), against an average of $23.3 million.
• Across the five-year window, Cash from Investing Activities surged 414.72% in 2022 and slumped 272.53% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $80.4 million in 2022, then slumped by 182.8% to -$66.6 million in 2023, then soared by 187.48% to $58.2 million in 2024, then slumped by 55.31% to $26.0 million in 2025, then surged by 37.77% to $35.9 million in 2026.
• Per Business Quant, the three latest PACB Cash from Investing Activities figures stand at $35.9 million (Q1 2026), $26.0 million (Q4 2025), and $18.9 million (Q3 2025).